Walgreens Boots Alliance, Inc. (WBA) Quick Ratio (Acid-Test): 0.37
Is Walgreens Boots Alliance, Inc.’s quick ratio (acid-test) high or low?
Walgreens Boots Alliance, Inc.'s quick ratio (acid-test) of 0.37 is in line with its 5-year average of 0.35, near the high end of its 5-year range (0.30–0.38).
As of Saturday, June 13, 2026. 10.45% above its 12-month average of 0.33.
WBA Quick Ratio (Acid-Test) Chart
WBA Average Quick Ratio (Acid-Test) Chart
WBA Current vs Average Quick Ratio (Acid-Test) Chart
WBA Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
0.37
QUICK RATIO (ACID-TEST) AVG TTM
0.33
QUICK RATIO (ACID-TEST) AVG 3Y
0.35
QUICK RATIO (ACID-TEST) AVG 5Y
0.35
QUICK RATIO (ACID-TEST) AVG 10Y
0.49
QUICK RATIO (ACID-TEST) AVG 15Y
0.52
QUICK RATIO (ACID-TEST) AVG 20Y
0.53
CURRENT VS TTM AVG
+10.45%
CURRENT VS 3Y AVG
+5.71%
CURRENT VS 5Y AVG
+6.73%
CURRENT VS 10Y AVG
-24.49%
CURRENT VS 15Y AVG
-28.76%
CURRENT VS 20Y AVG
-30.50%
WBA Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Walgreens Boots Alliance, Inc. (WBA) | $10.37B | 0.37 | 0.33 | 0.35 | 0.35 |
| Baxter International Inc. (BAX) | $10.77B | 1.56 | 1.31 | 1.23 | 1.40 |
| Charles River Laboratories International, Inc. (CRL) | $9.03B | 1.02 | 1.07 | 1.10 | 1.11 |
| Tempus AI, Inc. (TEM) | $8.35B | 3.00 | 2.58 | 2.23 | 3.05 |
| Align Technology, Inc. (ALGN) | $12.52B | 1.24 | 1.17 | 1.11 | 1.16 |
| Bio-Rad Laboratories, Inc. (BIO) | $7.73B | 4.19 | 4.52 | 4.42 | 3.69 |
| The Cooper Companies, Inc. (COO) | $13.24B | 1.13 | 1.13 | 0.99 | 0.98 |
| Solventum Corporation (SOLV) | $13.66B | 0.89 | 0.86 | 0.93 | 0.94 |
| Hims & Hers Health, Inc. (HIMS) | $5.98B | 1.61 | 1.56 | 2.48 | 3.39 |
| Hologic, Inc. (HOLX) | $16.97B | 3.06 | 3.04 | 3.12 | 2.66 |
Liquidity Comparison
Quick Ratio
0.37
Excludes inventory
Current Ratio
0.68
Includes inventory
Walgreens Boots Alliance, Inc. Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Walgreens Boots Alliance, Inc. Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Walgreens Boots Alliance, Inc. (WBA)?
- The quick ratio (acid-test) for WBA stock is 0.37.
- Is Walgreens Boots Alliance, Inc.'s quick ratio (acid-test) high or low?
- Walgreens Boots Alliance, Inc.'s quick ratio (acid-test) of 0.37 is in line with its 5-year average of 0.35, near the high end of its 5-year range (0.30–0.38).
- What is the TTM average quick ratio (acid-test) for Walgreens Boots Alliance, Inc. (WBA)?
- The TTM average quick ratio (acid-test) for WBA stock is 0.33.
- What is the 3Y average quick ratio (acid-test) for Walgreens Boots Alliance, Inc. (WBA)?
- The 3Y average quick ratio (acid-test) for WBA stock is 0.35.
- What is the 5Y average quick ratio (acid-test) for Walgreens Boots Alliance, Inc. (WBA)?
- The 5Y average quick ratio (acid-test) for WBA stock is 0.35.
- What is the 10Y average quick ratio (acid-test) for Walgreens Boots Alliance, Inc. (WBA)?
- The 10Y average quick ratio (acid-test) for WBA stock is 0.49.
- What is the 15Y average quick ratio (acid-test) for Walgreens Boots Alliance, Inc. (WBA)?
- The 15Y average quick ratio (acid-test) for WBA stock is 0.52.
- What is the 20Y average quick ratio (acid-test) for Walgreens Boots Alliance, Inc. (WBA)?
- The 20Y average quick ratio (acid-test) for WBA stock is 0.53.
Walgreens Boots Alliance, Inc. Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2024-08-31 | 0.37 |
| 2023-08-31 | 0.30 |
| 2022-08-31 | 0.38 |
| 2021-08-31 | 0.35 |
| 2020-08-31 | 0.32 |
| 2019-08-31 | 0.36 |
| 2018-08-31 | 0.38 |
| 2017-08-31 | 0.59 |
| 2016-08-31 | 0.99 |
| 2015-08-31 | 0.66 |
| 2014-08-31 | 0.69 |
| 2013-08-31 | 0.57 |
| 2012-08-31 | 0.43 |
| 2011-08-31 | 0.53 |
| 2010-08-31 | 0.61 |
| 2009-08-31 | 0.78 |
| 2008-08-31 | 0.48 |
| 2007-08-31 | 0.40 |
| 2006-08-31 | 0.64 |
| 2005-08-31 | 0.61 |
| 2004-08-31 | 0.74 |
| 2003-08-31 | 0.63 |
| 2002-08-31 | 0.51 |
| 2001-08-31 | 0.30 |
| 2000-08-31 | 0.31 |
| 1999-08-31 | 0.39 |
| 1998-08-31 | 0.38 |
| 1997-08-31 | 0.41 |
| 1996-08-31 | 0.33 |
| 1995-08-31 | 0.33 |
Related Metrics
About Walgreens Boots Alliance, Inc.
Walgreens Boots Alliance, Inc., established in 1901 and based in Deerfield, Illinois, operates as a leading global retailer focused on pharmacy, health, and beauty products. Its business activities are organized into two primary divisions: the United States and International. In the United States, the company dispenses prescription drugs and offers a diverse selection of retail goods. This includes items for health, wellness, beauty, and personal care, alongside general merchandise and consumable products, all available through its extensive network of retail drugstores. The U.S. segment also provides specialized central pharmacy services and mail delivery options for prescriptions. As of August 31, 2021, this division managed 8,965 retail outlets under the Walgreens and Duane Reade banners, complemented by five specialty pharmacies. The International segment focuses on the sale of prescription medications, health and wellness items, beauty products, personal care essentials, and other consumer goods. These are sold through its pharmacy-centric health and beauty retail locations, optical practices, its online platform boots.com, and an integrated mobile application. Additionally, this segment engages in pharmaceutical wholesale and distribution operations within Germany. By August 31, 2021, the international portfolio included 4,031 retail stores operating under brands such as Boots, Benavides, and Ahumada, located across countries including the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile. It also oversaw 548 optical practices, with 160 of these operating as franchises.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Timothy C. Wentworth